ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Overview
Arrowhead Pharmaceuticals develops RNA interference-based medicines that silence disease-causing genes to treat intractable diseases across multiple therapeutic areas including cardiovascular, metabolic, neurological, and rare genetic disorders.
ARROWHEAD PHARMACEUTICALS, INC is a Healthcare company operating in Biotechnology with a $11.55B market cap.
Most recent reported earnings: Q2 FY2026 (Aug 5, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-02-0512 Q&A exchanges
- Q4 FY2025Earnings2025-11-2525 Q&A exchanges
- Q3 FY2025Earnings2025-08-0817 Q&A exchanges
- Q2 FY2025Earnings2025-05-1227 Q&A exchanges
- Q1 FY2025Earnings2025-02-1025 Q&A exchanges
- Q4 FY2024Earnings2024-11-2618 Q&A exchanges
- Q3 FY2024Earnings2024-08-0825 Q&A exchanges
- Q2 FY2024Earnings2024-05-0918 Q&A exchanges
- Q1 FY2024Earnings2024-02-0635 Q&A exchanges
- Q4 FY2023Earnings2023-11-2918 Q&A exchanges
- Q3 FY2023Earnings2023-08-0728 Q&A exchanges
- Q2 FY2023Earnings2023-05-0223 Q&A exchanges
- Q1 FY2023Earnings2023-02-0623 Q&A exchanges
- Q4 FY2022Earnings2022-11-2821 Q&A exchanges
- Q3 FY2022Earnings2022-08-0416 Q&A exchanges
- Q2 FY2022Earnings2022-05-1031 Q&A exchanges
- Q1 FY2022Earnings2022-02-0223 Q&A exchanges
- Q4 FY2021Earnings2021-11-2217 Q&A exchanges
- Q3 FY2021Earnings2021-08-0636 Q&A exchanges
- Q2 FY2021Earnings2021-05-0531 Q&A exchanges
- Q1 FY2021Earnings2021-02-0430 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-05EPS— vs $-1.17—Rev— vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-05 | — | $-1.17 | — | — | — | — | EODHD |
Source: EODHD. ARWR reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks ARWR's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 4/10 quarters with 80% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Missed in 3 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.31 | $2.38 | -2.9% | +3.3% | +2.3% |
| Q4 FY2026 | $2.54 | $2.56 | -0.6% | +6.5% | +5.2% |
| Q3 FY2026 | $2.42 | $2.51 | -3.7% | -1.3% | -2.0% |
| Q2 FY2026 | $2.66 | $2.46 | +8.0% | +8.7% | +5.9% |
| Q1 FY2025 | $2.35 | $2.43 | -3.3% | +3.7% | +3.9% |
| Q4 FY2025 | $2.85 | $2.64 | +8.1% | +3.4% | +4.8% |
| Q3 FY2025 | $2.71 | $2.71 | -0.1% | +1.4% | +2.5% |
| Q2 FY2025 | $2.51 | $2.53 | -0.9% | -0.2% | -0.6% |
| Q1 FY2024 | $2.97 | $2.69 | +10.5% | +8.2% | +7.5% |
| Q4 FY2024 | $2.44 | $2.56 | -4.6% | +1.2% | +4.1% |
Guidance change history
Sample- Q1 FY2026Maintained2026-04-15
- Q4 FY2026Maintained2026-13-15
- Q3 FY2026Suspended2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Maintained2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Maintained2025-10-15
- Q2 FY2025Maintained2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Christopher Richard AnzaloneCEO1 yr 4 mono recorded callsCurrentSample
CEO since 2025 • 3/4 beats (75%) • last guidance raise Q3 FY2026
- Daniel Joseph ApelCFO1 yr 2 mono recorded callsCurrentSample
CFO since 2025 • 3/4 beats (75%) • last guidance raise Q3 FY2026
- Patrick D O'BrienCOO6 mono recorded callsCurrentSample
COO since 2025 • 2/4 beats (50%) • last guidance raise Q1 FY2026
- James C HamiltonChief Medical Officer10 mo19 callsCurrentSample
OTHER_C_SUITE since 2025 • 2/4 beats (50%) • guidance suspended Q3 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ARWR.
$ curl https://api.spokenalpha.com/v1/companies/ARWRFAQ
Frequently asked about ARWR
Where can I find ARROWHEAD PHARMACEUTICALS, INC.'s (ARWR) earnings call transcripts?
Spoken Alpha indexes ARWR's earnings call transcripts at https://spokenalpha.com/companies/ARWR. Each call links to attributed speakers and parsed analyst Q&A.
When was ARROWHEAD PHARMACEUTICALS, INC.'s most recent earnings call?
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) held its most recent earnings call on 2026-02-05, covering fiscal Q1 2026.
What sector is ARWR in?
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) operates in the Healthcare sector (Biotechnology industry).